Sawyer & Company Inc Has $287,000 Holdings in McKesson Co. (NYSE:MCK)

Sawyer & Company Inc lessened its holdings in McKesson Co. (NYSE:MCK) by 34.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 503 shares of the company’s stock after selling 264 shares during the period. Sawyer & Company Inc’s holdings in McKesson were worth $287,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Acropolis Investment Management LLC lifted its stake in McKesson by 38.7% in the 4th quarter. Acropolis Investment Management LLC now owns 251 shares of the company’s stock valued at $143,000 after purchasing an additional 70 shares during the last quarter. Kathmere Capital Management LLC lifted its stake in shares of McKesson by 7.9% in the 4th quarter. Kathmere Capital Management LLC now owns 2,149 shares of the company’s stock valued at $1,225,000 after acquiring an additional 157 shares during the last quarter. Assenagon Asset Management S.A. grew its position in McKesson by 66.2% during the 4th quarter. Assenagon Asset Management S.A. now owns 251,333 shares of the company’s stock worth $143,237,000 after acquiring an additional 100,093 shares during the last quarter. Fifth Third Wealth Advisors LLC increased its holdings in McKesson by 17.2% in the 4th quarter. Fifth Third Wealth Advisors LLC now owns 846 shares of the company’s stock worth $482,000 after purchasing an additional 124 shares in the last quarter. Finally, Oak Thistle LLC boosted its stake in shares of McKesson by 3.7% during the fourth quarter. Oak Thistle LLC now owns 5,117 shares of the company’s stock valued at $2,916,000 after purchasing an additional 184 shares in the last quarter. Institutional investors and hedge funds own 85.07% of the company’s stock.

McKesson Stock Down 1.7 %

NYSE:MCK opened at $583.51 on Thursday. The firm has a market capitalization of $74.07 billion, a P/E ratio of 30.22, a P/E/G ratio of 1.25 and a beta of 0.52. McKesson Co. has a twelve month low of $464.42 and a twelve month high of $637.51. The company has a fifty day moving average of $595.09 and a 200-day moving average of $560.90.

McKesson (NYSE:MCK) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $7.07 earnings per share for the quarter, beating the consensus estimate of $6.88 by $0.19. The firm had revenue of $93.65 billion for the quarter, compared to analyst estimates of $89.33 billion. McKesson had a net margin of 0.77% and a negative return on equity of 207.50%. The business’s quarterly revenue was up 21.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $6.23 earnings per share. On average, analysts anticipate that McKesson Co. will post 32.73 EPS for the current fiscal year.

McKesson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, January 2nd. Shareholders of record on Monday, December 2nd were paid a dividend of $0.71 per share. The ex-dividend date of this dividend was Monday, December 2nd. This represents a $2.84 dividend on an annualized basis and a yield of 0.49%. McKesson’s dividend payout ratio (DPR) is presently 14.71%.

Insiders Place Their Bets

In other news, EVP Leann B. Smith sold 579 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $572.79, for a total value of $331,645.41. Following the transaction, the executive vice president now owns 864 shares in the company, valued at $494,890.56. This trade represents a 40.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.11% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on MCK shares. Leerink Partners cut their target price on shares of McKesson from $665.00 to $630.00 and set an “outperform” rating on the stock in a research report on Monday, October 7th. Wells Fargo & Company lifted their price target on shares of McKesson from $535.00 to $641.00 and gave the stock an “equal weight” rating in a report on Friday, December 13th. Citigroup decreased their price objective on McKesson from $713.00 to $677.00 and set a “buy” rating for the company in a report on Friday, January 10th. Deutsche Bank Aktiengesellschaft cut their target price on McKesson from $623.00 to $579.00 and set a “buy” rating on the stock in a report on Wednesday, September 25th. Finally, Bank of America cut their price objective on McKesson from $680.00 to $650.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Two investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $646.14.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.